Blood disorder specialist Fulcrum Therapeutics has agreed to what amounts to a reverse merger with Slate Medicines, a ...
Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities.
At this year’s NHS ConfedExpo, one message came through clearly: innovation is already improving care across the NHS, but we ...
The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July, with ...
DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the ...
Just a few weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for some of its key assets, including a Fabry disease therapy and its genomic medicine platforms. PTC ...
Lantheus Holdings, Inc., a Bedford, Massachusetts-headquartered radiopharmaceutical-focused company, announced on 14 th August that the US FDA has approved Tauklarify (florquinitau F 18 injection), ...
England is one of a handful of countries globally to have already exceeded the WHO benchmark of treating 80% of all known ...
First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...
AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...
Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results